BioStock: Immunicum delivers positive phase II data in AML

Swedish/Dutch biotech Immunicum has been taking huge strides towards its goal of delivering a new treatment for one of the most serious challenges within cancer therapy: tumour recurrence. The latest step forward came earlier this week in the form of positive interim phase II data from the company ADVANCE-II project in acute myeloid leukaemia patients.

Read the article at biostock.se:

https://www.biostock.se/en/2022/05/immunicum-delivers-positive-phase-ii-data-in-aml/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/